​

Medpace (MEDP) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MEDP Stock Forecast

Medpace (MEDP) stock forecast, based on 16 Wall Street analysts, predicts a 12-month average price target of $330.00, with a high of $330.00 and a low of $330.00. This represents a -33.68% decline from the last price of $497.59.

$300 $340 $380 $420 $460 $500 High: $330 Avg: $330 Low: $330 Last Closed Price: $497.59

MEDP Stock Rating

Medpace stock's rating consensus is Hold, based on 16 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (18.75%), 11 Hold (68.75%), 2 Sell (12.50%), and 0 Strong Sell (0.00%).

Hold
Total 16 2 11 3 0 Strong Sell Sell Hold Buy Strong Buy

MEDP Price Target Upside V Benchmarks

TypeNameUpside
StockMedpace-33.68%
SectorHealthcare Stocks 13.55%
IndustryDiagnostics & Research Stocks14.25%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$341.33
Last Closing Price$497.59$497.59$497.59
Upside/Downside---31.40%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 25-273-12
Aug, 25-282113
Jul, 25-211--13
Jun, 25-210--12
May, 25-210--12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 24, 2025Michael ChernyLeerink Partners$330.00$330.59-0.18%-33.68%
Oct 23, 2024Eric ColdwellRobert W. Baird$349.00$326.546.88%-29.86%
Sep 25, 2024David WindleyJefferies$345.00$355.82-3.04%-30.67%
Aug 01, 2024Jailendra SinghTruist Financial$415.00$382.528.49%-16.60%
Jul 08, 2024Eric ColdwellRobert W. Baird$469.00$404.1316.05%-5.75%
Jun 13, 2024Eric ColdwellRobert W. Baird$456.00$403.7412.94%-8.36%
May 28, 2024Ann HynesMizuho Securities$435.00$390.5511.38%-12.58%
Apr 23, 2024David WindleyJefferies$450.00$376.2619.60%-9.56%
Feb 15, 2024John SourbeerUBS$452.00$394.3414.62%-9.16%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 09, 2025JefferiesHoldHoldhold
Jul 23, 2025Cowen & Co.BuySelldowngrade
Jun 24, 2025BarclaysOutperformCautiousinitialise
Apr 22, 2025William BlairMarket Performdowngrade
Oct 22, 2024Cowen & Co.BuyBuyhold
Sep 27, 2024UBSBuyNeutraldowngrade
Sep 25, 2024JefferiesBuyHolddowngrade
May 29, 2024Cowen & Co.Buyinitialise
Apr 23, 2024JefferiesBuyupgrade
Feb 15, 2024UBSNeutralBuyupgrade

Financial Forecast

EPS Forecast

$0 $4 $8 $12 $16 $20 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.07$5.06$7.57$9.20$13.06----
Avg Forecast$3.74$4.78$6.97$8.64$11.94$12.52$14.32$16.54$18.08
High Forecast$3.87$4.94$7.34$8.97$12.02$12.68$15.97$17.31$18.76
Low Forecast$3.57$4.56$6.85$8.63$11.84$12.28$13.57$15.84$17.75
Surprise %8.82%5.86%8.61%6.48%9.38%----

Revenue Forecast

$500M $1B $2B $2B $3B $4B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$925.92M$1.14B$1.46B$1.89B$2.11B----
Avg Forecast$912.22M$1.14B$1.45B$1.89B$2.11B$2.21B$2.46B$2.76B$3.14B
High Forecast$935.90M$1.17B$1.51B$1.94B$2.17B$2.22B$2.48B$2.76B$3.23B
Low Forecast$879.22M$1.10B$1.43B$1.86B$2.08B$2.20B$2.43B$2.75B$3.09B
Surprise %1.50%-0.04%0.56%-0.02%0.12%----

Net Income Forecast

$100M $200M $300M $400M $500M $600M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$144.93M$181.39M$245.21M$282.81M$404.39M----
Avg Forecast$127.25M$159.74M$178.50M$282.62M$379.75M$403.41M$458.58M$527.76M$575.69M
High Forecast$152.70M$191.68M$214.20M$339.14M$382.61M$403.71M$508.54M$551.09M$597.27M
Low Forecast$101.80M$127.79M$142.80M$226.10M$376.88M$390.88M$432.23M$504.43M$565.27M
Surprise %13.89%13.56%37.38%0.07%6.49%----

MEDP Forecast FAQ

Is Medpace stock a buy?

Medpace stock has a consensus rating of Hold, based on 16 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 11 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Medpace is a neutral investment for most analysts.

What is Medpace's price target?

Medpace's price target, set by 16 Wall Street analysts, averages $330 over the next 12 months. The price target range spans from $330 at the low end to $330 at the high end, suggesting a potential -33.68% change from the previous closing price of $497.59.

How does Medpace stock forecast compare to its benchmarks?

Medpace's stock forecast shows a -33.68% downside, underperforming the average forecast for the healthcare stocks sector (13.55%) and underperforming the diagnostics & research stocks industry (14.25%).

What is the breakdown of analyst ratings for Medpace over the past three months?

  • September 2025: 0% Strong Buy, 16.67% Buy, 58.33% Hold, 25.00% Sell, 0% Strong Sell.
  • August 2025: 0% Strong Buy, 15.38% Buy, 61.54% Hold, 15.38% Sell, 7.69% Strong Sell.
  • July 2025: 0% Strong Buy, 15.38% Buy, 84.62% Hold, 0% Sell, 0% Strong Sell.

What is Medpace’s EPS forecast?

Medpace's average annual EPS forecast for its fiscal year ending in December 2025 is $12.52, marking a -4.13% decrease from the reported $13.06 in 2024. Estimates for the following years are $14.32 in 2026, $16.54 in 2027, and $18.08 in 2028.

What is Medpace’s revenue forecast?

Medpace's average annual revenue forecast for its fiscal year ending in December 2025 is $2.21B, reflecting a 4.62% increase from the reported $2.11B in 2024. The forecast for 2026 is $2.46B, followed by $2.76B for 2027, and $3.14B for 2028.

What is Medpace’s net income forecast?

Medpace's net income forecast for the fiscal year ending in December 2025 stands at $403.41M, representing a -0.24% decrease from the reported $404.39M in 2024. Projections indicate $458.58M in 2026, $527.76M in 2027, and $575.69M in 2028.